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2 The findings and conclusions in this presentation are those 
of the authors and do not necessarily represent the official 
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 The use of product trade names is for identification 
purposes only
Disclaimer
3Overview
 Background
 Safety monitoring update
from the Vaccine Adverse Event Reporting System (VAERS)
 Rapid Cycle Analysis (RCA)
from the Vaccine Safety Datalink (VSD)
 FDA assessment of Guillain-Barré syndrome following
recombinant zoster vaccine from Medicare data
 Summary and next steps
4Vaccine safety monitoring and research terms
Term Explanation
Adverse event An adverse medical or health event following vaccination (a temporally associated event), which may or may not be related to vaccination (i.e., coincidental).
Adverse reaction An adverse health event following vaccination where substantial evidence exists to suggest the event is causally related to vaccination. 
MedDRA A clinically-validated international medical terminology used by regulatory authorities to describe health outcomes and events.
ICD-10 and 9 A system used by physicians and other healthcare providers to classify and code diagnoses, symptoms and procedures associated with healthcare.
Automated analysis Analysis on administrative or claims data or non-chart/health record confirmed data.
Chart confirmed/ 
medical record 
confirmed case
A case where review of medical charts and records by physicians or medical personnel confirms the 
diagnosis as valid and with accurate onset relative to timing of vaccination. 
Incident case A new case occurring for the first time ever or during a specified time period.
Prevalent or non-
incident case
A case that has been diagnosed in the past prior to vaccination or prior the study period that has 
become part of the patient’s past medical history and therefore is not new.
Biologically plausible 
risk interval
The time interval following vaccination where it is biologically plausible, based on the best available 
science, that an observed adverse event could be related to vaccination.
Statistical signal
A finding from an analysis where a calculated value (i.e., the test statistic) exceeds a specified statistical 
threshold; a statistical signal does not necessarily represent a vaccine safety problem and requires 
further assessment before conclusions can be drawn.
5Recombinant Zoster Vaccine (RZV, Shingrix)
 Adjuvanted (AS01B) glycoprotein vaccine
 Licensed Oct 2017; preferentially recommended by ACIP for adults ≥50 years
• Live-attenuated zoster vaccine (ZVL, Zostavax) recommended for adults ≥60 years
 Initial post-licensure safety data presented at the Feb 2019 ACIP meeting
• Overall, safety profile of RZV consistent with pre-licensure clinical trial data 
• VAERS data indicated systemic signs and symptoms and local reactions were 
commonly reported; there were no findings of disproportional reporting for any 
pre-specified outcomes
• Statistical signal was detected for Guillain-Barré syndrome (GBS) in VSD RCA 
monitoring based on a small number of GBS cases using automated data
‒ Signal assessment in progress, including FDA analysis of Medicare data 
Safety monitoring update
from the Vaccine Adverse Event Reporting System (VAERS)
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Adverse
Event 
Reporting 
System
http://vaers.hhs.gov
8Vaccine Adverse Event Reporting System (VAERS)
Strengths
 National data 
 Accepts reports from anyone
 Rapidly detects safety signals 
 Can detect rare adverse events
 Data available to public
Limitations
 Reporting bias 
 Inconsistent data quality and 
completeness
 Lack of unvaccinated comparison group
 Generally cannot assess causality
• VAERS accepts all reports from all reporters without making judgments on 
causality, irrespective of clinical seriousness
• As a hypothesis generating system, VAERS identifies potential vaccine safety 
concerns that can be studied in more robust data systems
9Methods: VAERS monitoring and analysis
 Descriptive analysis of RZV reports from October 2017 through April 2019 
(as of May 10, 2019 )
• Signs, symptoms, and diagnoses coded using Medical Dictionary for 
Regulatory Activities (MedDRA) terms
 Reporting rates (based on 11.89 million RZV doses distributed for the U.S. market 
through March 2019, courtesy GSK)*
 Empirical Bayesian data mining to detect disproportional reporting for 
vaccine-adverse event pairings 
 Clinical review of reports (includes medical records when available):
• 20 pre-specified outcomes
*Reporting rates are adjusted using reports and RZV doses distributed through March 31, 2019 
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Pre-specified outcomes (based on pre-licensure trials and ZVL reports)
 Acute myocardial 
infarction
 Amyotrophic lateral 
sclerosis
 Anaphylaxis
 Autoimmune disorders
 Autoimmune vasculitis
 Bell’s Palsy
 Co-administration with 
another adjuvanted
vaccine 
 Death
 Gout
 Guillain-Barré syndrome
 Immune 
thrombocytopenia
 Inflammatory eye  
disease
 Lymphadenitis
 Meningitis
 Optic ischemic 
neuropathy
 Osteonecrosis
 Post-herpetic neuralgia
 Seizures / convulsions
 Stroke / CVA
 Supraventricular 
tachyarrhythmias
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Reports to VAERS 
following RZV
Report characteristics N (%)
Total reports 18,418
Female 12,431 (67.5)
Non-serious 17,919 (97.3)
Type of reporter
Manufacturer 6639 (36.0)
Healthcare professional 6372 (34.6)
Patient 4347 (23.6)
Other 1060 (5.8)
Age groups (years)
<50† 92 (0.5)
50-59 3759 (20.4)
60-69 6385 (34.7)
70-79 4019 (21.8)
80+ 1111 (6.0)
Not reported or unknown 3052 (16.6)
RZV given alone 17,363 (94.3)
 Reporting rates (based on 11.89 million 
doses distributed through March 2019 and reports 
through March 2019)  
• All reports: 154.3 per 100,000 
doses distributed
• Serious reports*: 3.9 per 100,000 
doses distributed
†RZV not approved for use in <50 y/o
*Based on the Code of Federal Regulations if one of the following 
is reported: death, life-threatening illness, hospitalization or 
prolongation of hospitalization or permanent disability (FDA 
routinely reviews all serious reports)
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Most common signs and symptoms in reports to VAERS 
following RZV and review of pre-specified outcomes
Signs and symptoms 
(MedDRA Preferred Terms)*
18,418 total reports
n (%)
Pyrexia (fever) 4625 (25.1)
Chills 3959 (21.5)
Injection site pain 3798 (20.6)
Pain 3731 (20.3)
Headache 3497 (19.0) 
Fatigue 3007 (16.3)
Pain in extremity 2986 (16.2)
Injection site erythema 2967 (16.1)
Myalgia 2208 (12.0)
Injection site swelling 2051 (11.1)
*Not mutually exclusive; a report may contain more than one MedDRA Preferred Term
 Systemic signs and 
symptoms and injection 
site reactions were the 
most commonly 
reported AEs
 No unexpected patterns 
detected by physician 
reviewers of reports of 
pre-specified outcomes 
13
Data mining
 Empirical Bayesian (EB) data mining identifies AEs that are 
reported more frequently than expected, adjusting for age, 
sex, and the year in which reports are received
• Identifies AEs that are reported at least twice as frequently as would be 
expected by chance following a given vaccine (i.e., lower bound of the 
90% confidence interval surrounding the EB geometric mean [EB05] >2)
 One empirical Bayesian data mining finding to date for RZV for 
the MedDRA PT:
• “Product administered to patient of inappropriate age” when looking 
at individuals aged 19-44.9 years old
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Summary of VAERS review of RZV reports
 RZV post-licensure safety monitoring findings in VAERS are 
generally consistent with the safety profile observed in pre-
licensure clinical trials
 Self-limited systemic signs and symptoms and injection site 
reactions were the most commonly reported adverse events
 Serious adverse events were rarely reported (2.7% of reports;  
similar to other vaccines given in same age group)
 No empirical Bayesian data mining findings for any RZV-AE 
pairings except for “Product administered to patient of 
inappropriate age”
Rapid Cycle Analysis (RCA)
from the Vaccine Safety Datalink (VSD)
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Vaccine Safety Datalink (VSD)
 Established in 1990 
 Collaboration between CDC and several integrated 
healthcare organizations 
 Medical care and demographic data on over 12.1 million 
persons per year (~3.7% of U.S. population)
 Links vaccination data to health outcome data
 Used for surveillance and research
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VSD electronic files + chart review 
Linked by 
study IDs
Images created by Wilson Joseph, Megan Mitchell, Ananth, and Iga from the noun project
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A powerful and sophisticated tool
 Near real-time vaccine-safety monitoring (using sequential monitoring techniques)
 Employs an automated analysis that uses ICD-coded diagnoses from administrative data
 A surveillance activity (signal detection and signal refinement), which is not the same as 
an epidemiologic study (signal evaluation, causality assessment)
 Requires careful thought and customization in the design, set-up, interpretation
Designed to detect statistical signals (values above specified statistical thresholds)
 When a statistical signal occurs, CDC conducts a series of evaluations using traditional 
epidemiologic methods
 Chart-confirmation of diagnoses to confirm or exclude cases as true incident cases is a 
key part of statistical signal assessment 
Not all statistical signals represent a true increase in risk for an adverse event
Rapid Cycle Analysis (RCA) in VSD
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Primary analysis for RZV RCA* is a historical 
comparator design
 Monthly near real-time 
sequential monitoring of 
pre-specified outcomes
 Uses ICD-10/9 coded 
diagnoses
 18 planned monthly 
analyses (1st at 6 months), 
with an 18 week data lag
 Presenting interim results 
of the 7th analysis
 Test statistic: Adjusted 
likelihood ratio test        
(H0: RR=1 versus HA: RR>1)
*Led by Kaiser Permanente Washington VSD site; Jennifer Nelson, PhD and Lisa Jackson, MD, MPH
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10 high priority pre-specified RZV RCA outcomes*
Acute myocardial infarction
Risk interval 
in days
1-42
Anaphylaxis 0-1
Bell’s palsy 1-42
Convulsion 1-42
Giant cell arteritis 1-42
Guillain-Barré syndrome 1-42
Optic ischemic neuropathy 1-42
Polymyalgia rheumatica 1-42
Stroke 1-42
Supraventricular tachycardia 1-42
*Other outcomes for descriptive analysis only include: gout, keratitis, non-specific adverse effects, stroke subtypes,
pneumonia, keratitis, uveitis and retinitis, zoster ocular disease, systemic reactions, local reactions, urgent care or
emergency department visits
High priority pre-specified outcomes
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Secondary analyses for RZV RCA uses 2 concurrent 
comparators
1. Had an ICD-10 coded well-visit during RZV uptake period
2. Received another vaccine (not influenza – e.g., PPSV23, 
PCV13, Td, Tdap, etc.) during RZV uptake period
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Results: RZV uptake at VSD sites for 7th analysis
211,109 doses admin thru 
Dec 2018, with follow-up 
for outcomes thru Apr 2019
Doses admin 
thru Dec 2018
F/U thru 
Apr 2019
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RZV RCA results: statistical signals for Bell’ palsy and GBS detected
High priority outcomes Obs events Exp events 
Obs rate 
(per 100K) RR 
Statistical signal
(which analysis)
Stroke 109 126 51.6 0.87 No
Acute MI 106 125 50.2 0.85 No
Polymyalgia rheumatic 35 53 16.6 0.66 No
Supraventricular tachycardia 34 42 16.1 0.82 No
Convulsion assoc. terms 45 40 21.3 1.11 No
Bell’s palsy1 40 31 18.9 1.31 Yes (at #5)
Anaphylaxis 7 5 3.3 1.32 No
Giant cell arteritis 10 17 4.7 0.61 No
Optic ischemic neuropathy 14 17 6.6 0.83 No
Guillain-Barré syndrome (GBS)2 5 1.6 2.4 3.18 Yes (at #2)
1Bell’s palsy signaled at 5th analysis (36 obs events vs. 24 exp; RR=1.51, adjusted p=0.03)
2GBS signaled at 2nd analysis (3 obs events vs. 0.6 exp; RR=5.25, adjusted p=0.02)
Bell’s palsy
statistical signal assessment
26
 RCA statistical signal at 5th analysis: RR=1.51 (36 obs vs. 24 exp events, p=0.03) 
 At 7th analysis, attenuated somewhat: RR=1.31 (40 obs vs. 31 exp events)
 RRs not consistently elevated for concurrent comparator groups
• Well-visits RR=0.98, other non-influenza vaccine recipients RR=0.74
 Chart review adjudication performed on the 36 RZV cases (from 5th analysis)
• 21 cases ruled out (11 prevalent/non-incident; 5 miscoded; 2 diagnosis overturned; 
3 outside 1-42 day risk window)
• 15 definite cases with onset within 1-42 day window
Bell’s palsy signal assessment in VSD
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VAERS reports of Bell’s palsy following RZV 
(Oct 2017-Apr 2019)
 No empirical Bayesian data mining finding for RZV-Bell’s palsy
 Proportional Reporting Ratio analysis did not detect any disproportional reporting for 
RZV-Bell’s palsy when ZVL, IIV or PPSV23 vaccines were used as comparators
 59 reports had a MedDRA PTs for Bell’s palsy or facial paralysis assigned; upon review:
• 10 case reports met Brighton criteria for Bell’s palsy: level 1 (4), level 2 (0), level 3 (6)
• 6 case reports did not meet Brighton criteria or had insufficient information, but were 
explicitly described as physician-diagnosed Bell’s palsy
• 43 case reports did not meet Brighton criteria and were not physician diagnosed
 Of the 16 cases that met Brighton criteria level 1-3, or were physician diagnosed:
• 14 had symptom onset w/in a 0-42 day risk window following RZV (1 w/concurrent IIV)
- Translates to reporting rate of 1.2 Bell’s palsy cases per million RZV doses distributed*
*Reporting rates are adjusted using reports and RZV doses distributed through March 31, 2019
Guillain-Barré syndrome (GBS)
statistical signal assessment 
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RZV RCA results: statistical signals for Bell’ palsy and GBS detected
High priority outcomes Obs events Exp events 
Obs rate 
(per 100K) RR 
Statistical signal
(which analysis)
Stroke 109 126 51.6 0.87 No
Acute MI 106 125 50.2 0.85 No
Polymyalgia rheumatic 35 53 16.6 0.66 No
Supraventricular tachycardia 34 42 16.1 0.82 No
Convulsion assoc. terms 45 40 21.3 1.11 No
Bell’s palsy 40 31 18.9 1.31 Yes (at #5)
Anaphylaxis 7 5 3.3 1.32 No
Giant cell arteritis 10 17 4.7 0.61 No
Optic ischemic neuropathy 14 17 6.6 0.83 No
Guillain-Barré syndrome (GBS)1 5 1.6 2.4 3.18 Yes (at #2)
1GBS signaled at 2nd analysis (3 obs events vs. 0.6 exp; RR=5.25, adjusted p=0.02); at 7th analysis, 5 observed ICD-
10 coded GBS cases following RZV
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GBS statistical signal assessment in VSD
 Chart review of the 5 ICD-10 coded GBS cases following RZV
Case ruled out: prior diagnosis of GBS, no recurrence or exacerbation after 
RZV, not a true incident case 
Case ruled out: prior diagnosis of GBS, no recurrence or exacerbation after 
RZV, not a true incident case
Case ruled out: GBS symptom onset prior to vaccination
Confirmed case: Brighton Criteria* level 2 GBS case with onset in risk window, 
also received simultaneous PCV13
Confirmed case: Brighton Criteria level 3 GBS case with onset in risk window, 
probable respiratory infection prior to GBS symptom onset
*Sejvar et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of 
immunization safety data. Vaccine. 2011;29(3):599-612. 
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GBS statistical signal assessment in VSD (cont.)
 Chart review of the 5 total ICD-9/10 coded GBS cases in the 
historical ZVL comparator
Case ruled out: prior diagnosis of GBS, no recurrence or exacerbation after 
RZV, not a true incident case 
Case ruled out: upon chart review, case given alternative diagnosis of chronic 
inflammatory demyelinating polyneuropathy (CIDP)  
Unable to confirm case: medical records not available
Confirmed case: Brighton Criteria* level 2 GBS case with onset in risk window
Confirmed case: Brighton Criteria level 2 GBS case with onset in risk window
*Sejvar et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of 
immunization safety data. Vaccine. 2011;29(3):599-612. 
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Range
 
1Sejvar et al. Population incidence of 
Guillain-Barré syndrome: a 
systematic review and meta-analysis. 
Neuroepidemiology. 2011;36:123-33.
2Using data from Shui et al. Guillain-
Barré syndrome incidence in a large 
United States cohort (2000-2009). 
Neuroepidemiology. 2012;39:109-15.
 To date, the estimated VSD chart confirmed GBS rate in the current RZV cohort is higher than in the 
historical ZVL cohort and higher than published estimates in the literature1,2
 Uncertainty around the VSD estimated GBS rate following RZV is large, IR=8.2 (95% CI 1.0, 29.7), and 
overlapping with the background rates reported in the literature
Comparison of GBS incidence rates in 50+ y/o 
(per 100K person years)
Chart confirmed GBS IR in VSD RZV cohort
(point estimate, 95% CI) based on 2 cases
Chart confirmed GBS IR in historical VSD 
ZVL cohort (point estimate, 95% CI) 
based on 2 cases
Range of GBS IRs from systematic review 
and meta-analysis1
GBS IR from data from VSD analysis, 
2000-2009 (point estimate, 95% CI)2
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GBS statistical signal assessment in VSD
 Chart review of the 5 total ICD-9/10 coded GBS cases in the 
historical ZVL comparator
Case ruled out: prior diagnosis of GBS, no recurrence or                  
exacerbation after RZV, not a true incident case 
Case ruled out: upon chart review, case given alternative diagnosis                  
of chronic inflammatory demyelinating polyneuropathy (CIDP)  
Unable to confirm case: medical records not available
Confirmed case: Brighton Criteria* level 2 GBS case with onset in risk window
Confirmed case: Brighton Criteria level 2 GBS case with onset in risk window
*Sejvar et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of 
immunization safety data. Vaccine. 2011;29(3):599-612. 
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Sensitivity analysis: comparison of GBS incidence 
rates in 50+ y/o (per 100K person years)
t 
Range
Incidence rates
.
2.4
IR based on 2 
confirmed cases only 
from previous slide
Chart confirmed GBS IR in VSD RZV cohor
(point estimate, 95% CI) based on 2 cases
GBS IR in historical VSD ZVL cohort 
(point estimate, 95% CI) based on 3 
cases (includes unconfirmed case)
Range of GBS IRs from systematic review 
and meta-analysis1
GBS IR estimate from VSD analysis 2000-
2009 (point estimate)2
1Sejvar et al. Population incidence of 
Guillain-Barré syndrome: a systematic 
review and meta-analysis. 
Neuroepidemiology. 2011;36:123-33.
2Using data from Shui et al. Guillain-Barré
syndrome incidence in a large United 
States cohort (2000-2009). 
Neuroepidemiology. 2012;39:109-15.
RR=2.3 (95% CI 0.2, 20.2)
RD=4.7 per 100,000 PYs 
(95% CI -7.4, 16.8)
 Including unconfirmed GBS case in the historical ZVL cohort as a true incident case (3 total cases):
• ZVL vaccinated IR increases from: IR=2.4 (95% CI 0.3, 8.6) to IR 3.6 (95% CI 0.7, 10.4)
• RR decreases from: RR=3.5 (95% CI 0.3, 47.8) to RR=2.3 (95% CI 0.2, 20.2)
• RD decreases from: RD=5.9 per 100K PYs (95% CI -6.0, 17.7) to RD=4.7 per 100K PYs (95% CI -7.4, 16.8)
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VAERS reports of GBS following RZV (Oct 2017-Apr 2019)
 No empirical Bayesian data mining finding for GBS
 Proportional Reporting Ratio analysis did not detect any disproportional reporting 
for RZV-GBS when either ZVL, IIV or PPSV23 vaccines were used as comparators
 46 reports had a MedDRA Preferred Term for GBS assigned; upon review:
• 24 case reports met Brighton criteria for GBS: level 1 (2), level 2 (17), level 3 (5)
‒ 2 described URI/ILI symptoms 2-3 weeks before GBS
• 7 case reports did not meet Brighton criteria or had insufficient information, but were 
explicitly described as physician-diagnosed GBS
• 15 case reports did not meet Brighton criteria and were not physician diagnosed
 Of the 31 cases that met Brighton criteria level 1-3, or were physician diagnosed:
• 29 had symptom onset w/in a 0-42 day risk window following RZV (1 w/concurrent IIV)
‒ Translates to reporting rate of 2.4 GBS cases per million RZV doses distributed*
*Reporting rates are adjusted using reports and RZV doses distributed through March 31, 2019
FDA assessment of Guillain-Barré syndrome 
following recombinant zoster vaccine (RZV)
from Medicare data
FDA assessment of the risk of Guillain-Barré syndrome (GBS) 
following recombinant zoster vaccine (RZV) in Medicare data
Slides and content courtesy Rich Forshee, PhD
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Background
• Upon detection of the statistical signal for GBS following RZV in the 
VSD RCA in the fall of 2018, CDC consulted with FDA on the 
possibility of additional analyses in other databases
• Subsequently, FDA in collaboration with CDC and CMS initiated an 
assessment of risk of GBS following RZV in Medicare data
• Interim results of an automated (ICD-coded) analysis are available
• Additional work to refine the analysis is in progress  
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Methods
• Replication of signaling VSD analysis
– Cohort comparison of the post-vaccination GBS rate between a vaccinated RZV 
population and a historical vaccinated ZVL population
• Population
– Exposure: Vaccinations identified using National Drug Codes (NDCs) in Part D
• RZV vaccination window: Oct 2017 – Dec 2018
• ZVL vaccination window: Oct 2012 – Sep 2017
– Aged into Medicare (65 years or older)
– Continuous enrollment in Medicare Parts A, B and D for 365 days prior to 
vaccination
• Clean period: No GBS in 365 days prior to vaccination date
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Methods
• Risk window: Days 1-42 post-vaccination
• Outcome: Primary inpatient Guillain-Barré syndrome (GBS) 
diagnosis
– ICD-9: 357.0
– ICD-10: G61.0
• Poisson model: log�𝐸𝐸  (𝑌𝑌  |𝑋𝑋  � = 0 + 1 ∗  +  + log(𝑡𝑡  )  
𝑌𝑌 =  𝐺𝐺𝐺𝐺𝐺𝐺 𝑜𝑜𝑜𝑜𝑡𝑡𝑉𝑉𝑜𝑜𝑜𝑜𝑉𝑉 𝑣𝑣𝑉𝑉𝑣𝑣𝑉𝑉𝑉𝑉𝑣𝑣𝑣𝑣𝑉𝑉 
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 = 𝐺𝐺𝑉𝑉𝑉𝑉𝑉𝑉𝑣𝑣𝐵𝐵 𝑣𝑣𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝑉𝑉𝑜𝑜ℎ𝑜𝑜𝑣𝑣𝑡𝑡 𝑡𝑡𝑉𝑉𝑣𝑣𝑜𝑜 (𝐺𝐺ℎ𝑉𝑉𝑉𝑉𝑖𝑖𝑣𝑣𝑉𝑉𝑖𝑖 𝑣𝑣𝑣𝑣. 𝑍𝑍𝑜𝑜𝑣𝑣𝑡𝑡𝑉𝑉𝑣𝑣𝑉𝑉𝑖𝑖) 
𝑋𝑋 = 𝐶𝐶𝑜𝑜𝑣𝑣𝑉𝑉𝑣𝑣𝑉𝑉𝑉𝑉𝑡𝑡𝑉𝑉𝑣𝑣 
𝑡𝑡 = 𝑉𝑉𝑖𝑖𝑒𝑒𝑜𝑜𝑣𝑣𝑜𝑜𝑣𝑣𝑉𝑉 𝑡𝑡𝑉𝑉𝑜𝑜𝑉𝑉 
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Plot of temporal distribution of GBS cases
915
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GBS outcome rates and model results
Cohort ICD-codedGBS cases
Eligible
doses 
Total person time
(100,000
person-days)
Outcome rate
(per 100,000
person-days)
Rate ratio (95% CI)
adjusted for age 
and sex
RZV
vaccinated 15 1,318,004 514.9 0.029
2.34 (1.01, 5.41)
p=0.047
ZVL 
vaccinated 9 1,817,099 753.4 0.012 ---
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GBS outcome rates and model results (cont.)
Cohort ICD-codedGBS cases
Eligible
doses 
Outcome rate
(per million doses)
Rate ratio (95% CI)*
adjusted for age 
and sex
Attributable risk (95% CI)
(per million doses)
adjusted for age and sex
RZV vax 15 1,318,004 11.38 2.34 (1.01, 5.41) 6.54 (-0.11, 13.9)
ZVL vax 9 1,817,099 4.95 --- ---
*Based on outcome rates of GBS cases per 100,000 person-days
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Summary
• Interim results of the FDA cohort comparison of post-vaccination GBS rate 
between vaccinated RZV population and historical ZVL population indicate:
– An elevated adjusted rate ratio=2.34 (95% CI 1.01, 5.41), p=0.047
• Results should be interpreted with caution
– This is an automated analysis using ICD-coded GBS diagnoses; chart 
review/confirmation of cases is pending
– Current vs. historical comparisons are subject to potential confounding and 
require adjustments, which are in progress
• A chart confirmed self-controlled analysis is planned, which will control for 
many potential confounders of historical comparator designs
Selected secondary outcomes 
and secondary analyses 
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 Descriptive analyses for lower priority outcomes in historical 
comparator (ZVL) design
• RR <1: hemorrhagic stroke (0.48) gout (0.84), pneumonia (0.65), zoster ocular (0.63)
• RR~1: non-hemorrhagic stroke (0.95), local rxns (0.96), uveitis/retinitis (0.89), urgent 
care/emergency dept. visit (0.90)
• RR >1: systemic rxns (1.21), non-specific AE (1.23), and keratitis (1.15)
 Well visit comparators (50+ yo) during RZV uptake period (N=1,415,492)
• All high priority outcomes RR <1.0 except GBS (RR=1.86; 5 obs vs. 2.7 exp events)
 Other (non-influenza) vaccine recipient comparators (50+ yo) during RZV 
uptake (N=518,115)
• All high priority outcomes RR <1.0 except GBS (RR=1.53; 5 obs vs. 3.3 exp events)
Secondary outcomes and comparators for RZV RCA
Summary and next steps
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 Still in the initial uptake period for RZV and early in the post-
licensure monitoring process, considering constraints on supply
• 11.89 million RZV doses distributed for the U.S. market through March 2019
• 211,109 RZV doses included in 7th (of 18) VSD RCA analysis covering the 
period Jan-Dec 2018, with outcome monitored through April 2019 
• 1,318,004 RZV doses included in the FDA Medicare data analysis; 
vaccination window Oct 2017-Dec 2018
RZV uptake
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Summary of post-licensure RZV monitoring
 No concerning patterns or findings of disproportional 
reporting for adverse health events in VAERS
 Statistical signals detected for Bell’s palsy and GBS in VSD 
RCA in automated analyses 
 Elevated rate ratio for GBS detected in the FDA cohort 
analysis in Medicare data using automated analysis
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Summary of post-licensure RZV monitoring (cont.)
Assessment of statistical signal for Bell’s palsy in VSD
 Statistical signal for Bell’s palsy in VSD RCA is not consistent 
across comparators
• RR=1.31 at 7th analysis (attenuated from RR=1.51 at 5th [signaling] analysis)
• RR=0.98 comparing to well-visits
• RR=0.74 comparing to other non-influenza vaccine recipients
 Ongoing Bell’s palsy chart review/confirmation indicates 15 of 36 
presumptive cases confirmed in 1-42 day risk window
51
Summary of post-licensure RZV monitoring (cont.)
Assessment of statistical signal for GBS in VSD
 Assessment in VSD has included chart review of all potential 
GBS cases identified by ICD codes in current RZV and historical 
ZVL recipients
• Chart confirmed RR=3.5 (95% CI 0.3, 47.8) based on 2 RZV and 2 ZVL 
confirmed cases
‒ Risk Difference=5.9 per 100,000 PYs (95% CI -6.0, 17.7)
• If the ‘unconfirmed’ GBS case in the ZVL comparator group is included 
as a true incident case, RR changes to RR=2.3 (95% CI 0.2, 20.2)
‒ Risk Difference=4.7 per 100,000 PYs (95% CI -7.4, 16.8)
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Summary of post-licensure RZV monitoring (cont.)
FDA assessment of GBS risk following RZV from Medicare data
 Interim results of the FDA cohort comparison of post-
vaccination GBS rates between vaccinated RZV population 
and historical ZVL population using ICD-coded cases 
showed elevated rate ratio
• Additional analysis and chart review/confirmation pending
Rate ratio (95% CI)
adjusted for age and sex
Attributable risk (95% CI)
(per million doses)
adjusted for age and sex
2.34 (1.01, 5.41) 6.54 (-0.11, 13.9)
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Final thoughts and next steps
 Safety profile of RZV is generally consistent with pre-licensure clinical trial data
 Two systems have detected an increased risk for GBS; however, numbers are small in 
VSD and chart reviews are pending in FDA Medicare analysis 
 CDC will continue to monitor GBS (and Bell’s palsy) in VSD
• Track additional cases of GBS, conduct rapid chart review, estimate RR for chart-
confirmed GBS over time as more data accumulate, and consider SCRI analysis
• Track additional cases of Bell’s palsy; consider conducting chart review for cases 
following ZVL to estimate a chart-confirmed RR at end of surveillance period
 FDA is in the process of accessing charts to review GBS cases in the Medicare cohort 
analysis and will consider doing a chart confirmed self-controlled analysis to further 
assess risk of GBS following RZV
 Initial safety monitoring data so far are insufficient to conclude that a safety problem 
exists for GBS, but further evaluation and continued vigilance are warranted
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